Cardiol Therapeutics (CRDL) Receivables (2020 - 2026)

Cardiol Therapeutics' Receivables history runs 7 years deep, the most recent figure standing at $247715.5 for Q1 2026.

• Quarterly Receivables rose 2.53% year-over-year to $247715.5 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $247715.5 (up 2.53% YoY) and the FY2025 annual result came in at $162201.3, down 37.34% from the prior year.
• Receivables was $247715.5 for Q1 2026 at Cardiol Therapeutics, up from $162201.3 in the prior quarter.
• Across five years, Receivables topped out at $383685.8 in Q1 2022 and bottomed at $142333.3 in Q3 2025.
• A 5-year average of $251565.0 and a median of $247715.5 in 2026 frame the typical range for Receivables.
• Annual changes were most pronounced in 2022 — Receivables sank 43.12% — and 2024, when it increased 25.92%.
• Cardiol Therapeutics' Receivables stood at $353762.5 in 2022, then sank by 41.89% to $205575.9 in 2023, then advanced by 25.92% to $258866.1 in 2024, then tumbled by 37.34% to $162201.3 in 2025, then soared by 52.72% to $247715.5 in 2026.
• Business Quant data shows CRDL's Receivables at $247715.5 in Q1 2026, $162201.3 in Q4 2025, and $142333.3 in Q3 2025.